Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib.

Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib.

Item
http://www.wikidata.org/entity/Q38742492
"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitorsRucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer.Rucaparib: First Global Approval.Radiation Treatment in Women with Ovarian Cancer: Past, Present, and FutureCombination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression.PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer.Targeted treatment of advanced ovarian cancer: spotlight on rucaparib
P2860

Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib.

Item
http://www.wikidata.org/entity/Q38742492
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Ovarian Cancers Harbor Defects ...... ng in Resistance to Rucaparib.
@en
type
label
Ovarian Cancers Harbor Defects ...... ng in Resistance to Rucaparib.
@en
prefLabel
Ovarian Cancers Harbor Defects ...... ng in Resistance to Rucaparib.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P932
P356
P1433
P1476
Ovarian Cancers Harbor Defects ...... ng in Resistance to Rucaparib.
@en
P2093
P2860
P304
P31
P356
10.1158/1078-0432.CCR-16-0564
P407
P433
P478
P50
P577
P698
P921
P932